Invitrogen™ FGFR4 Recombinant Rabbit Monoclonal Antibody (14H10L9)

Description

This antibody is predicted to react with equine, mouse, rabbit and rat based on sequence homology. Intact IgG appears on a non-reducing gel as ~150 kDa band and upon reduction generating a ~25 kDa light chain band and a ~50 kDa heavy chain. Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

FGFR4 is a member of the FGFR family of receptor tyrosine kinases. This family is known to regulate a host of cellular functions including angiogenesis, mitogenesis, osteogenesis, myogenesis, carcinogenesis, cellular differentiation, and tissue repair after injury. The FGFR family has also been implicated in a number of diseases including cancer, rheumatoid arthritis, and diabetic retinopathy. FGFR4 is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. FGFR4 plays a role in postnatal lung development and may be involved in the development of skeletal muscle cell lineages.